OWC Pharmaceutical Research (OWCP) Stock Price, News & Analysis

Company Overview

OWC Pharmaceutical Research Corp is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel prodrug therapies. Using its proprietary chemistry platform, the company seeks to improve the bioavailability and therapeutic profiles of existing and new pharmaceutical agents, with a focus on central nervous system (CNS) disorders.

The company’s pipeline includes multiple preclinical candidates aimed at neurodegenerative and neurological conditions such as Parkinson’s disease, Alzheimer’s disease, multiple sclerosis and migraine. By modifying active drug molecules into prodrug forms, OWC Pharmaceutical Research aims to enhance pharmacokinetics, increase efficacy and reduce side-effect burdens. The company continues to advance its programs through ongoing research collaborations and preclinical development activities.

Headquartered in the United States, OWC Pharmaceutical Research is led by Chief Executive Officer Ira M. van de Roer, who brings extensive experience in drug development and corporate leadership. The company partners with academic institutions and contract research organizations across North America to support its mission of bringing improved prodrug therapies to patients in need.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 273,602 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Cannabis
• Current Symbol: OTCMKTS:OWCP
• CIK: 1431934
• Web: www.owcpharma.com
• Phone: 972722608004
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A